Advertisement
Canada markets open in 1 hour 25 minutes

  • S&P/TSX

    22,375.83
    +116.63 (+0.52%)
     

  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     

  • DOW

    39,387.76
    +331.36 (+0.85%)
     

  • CAD/USD

    0.7311
    -0.0000 (-0.00%)
     

  • CRUDE OIL

    79.80
    +0.54 (+0.68%)
     

  • Bitcoin CAD

    86,768.55
    +3,180.91 (+3.81%)
     

  • CMC Crypto 200

    1,306.10
    -51.91 (-3.82%)
     

  • GOLD FUTURES

    2,379.10
    +38.80 (+1.66%)
     

  • RUSSELL 2000

    2,073.63
    +18.49 (+0.90%)
     

  • 10-Yr Bond

    4.4490
    -0.0430 (-0.96%)
     

  • NASDAQ futures

    18,281.75
    +67.25 (+0.37%)
     

  • VOLATILITY

    12.79
    +0.10 (+0.79%)
     

  • FTSE

    8,451.54
    +70.19 (+0.84%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6778
    0.0000 (0.00%)
     

CRMD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 20, 2021 in the Class Action Filed on Behalf of CorMedix Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - August 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CorMedix Inc. (NASDAQ: CRMD) alleging that the Company violated federal securities laws.

Class Period: July 8, 2020 and May 13, 2021
Lead Plaintiff Deadline: September 20, 2021
No obligation or cost to you.

Learn more about your recoverable losses in CRMD:
https://www.kleinstocklaw.com/pslra-1/cormedix-inc-loss-submission-form?id=18210&from=5

CorMedix Inc. NEWS - CRMD NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in CorMedix you have until September 20, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased CorMedix securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the CRMD lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92016